SCHEMBL220863

SCHEMBL220863

Cc1cc(Nc2cc(N3CCOCC3)nc(N[C@@H](C)c3ncc(F)cn3)n2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 13/20 1.00
JAK2 O60674 14/20 0.86
AURKA O14965 5/20 0.58
AURKB Q96GD4 2/20 0.58
KCNH2 Q12809 1/20 0.56
IGF1R P08069 1/20 0.55
PLK4 O00444 1/20 0.55
STK10 O94804 1/20 0.55
PAK4 O96013 1/20 0.55
NTRK1 P04629 1/20 0.55
RET P07949 1/20 0.55
FGFR1 P11362 1/20 0.55
FER P16591 1/20 0.55
CSNK2A2 P19784 1/20 0.55
JAK1 P23458 1/20 0.55
TYK2 P29597 1/20 0.55
FLT3 P36888 1/20 0.55
STAT3 P40763 1/20 0.55
STAT5A P42229 1/20 0.55
CDK3 Q00526 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4987053 0.93 JAK3 (1.00) JAK3JAK2AURKAAURKBPLK4
SCHEMBL220721 0.89 JAK3 (0.79) JAK3JAK2AURKAAURKBKCNH2
SCHEMBL13942846 0.88 JAK3 (0.78) JAK3JAK2KCNH2IGF1RNTRK1
SCHEMBL13943376 0.86 JAK3 (0.76) JAK3JAK2AURKAAURKBPLK4
SCHEMBL220017 0.85 JAK3 (0.88) JAK3JAK2AURKAAURKBPLK4
SCHEMBL13494392 0.83 JAK3 (0.71) JAK3JAK2AURKAKCNH2NTRK1
SCHEMBL2339473 0.83 JAK2 (1.00) JAK3JAK2KCNH2NTRK1JAK1
SCHEMBL220867 0.80 JAK2 (0.72) JAK3JAK2AURKAAURKBPLK4
SCHEMBL2336819 0.79 JAK2 (0.79) JAK3JAK2KCNH2
SCHEMBL2360999 0.79 JAK2 (0.79) JAK3JAK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088784-B2 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer ASTRAZENECA AB (SE) 2012-01-03 US disclosed